eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
3/2002
vol. 27
 
Share:
Share:
more
 
 
abstract:

Clinical immunology

Differential expression intensity of CD58 and HLA-DR on myeloblasts in acute myeloid leukaemia (AML)

Joanna Kopeć-Szlęzak
,
Jolanta Woźniak

Online publish date: 2003/12/15
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The CD58 (LFA-3) and HLA-DR expression intensity on leukemic cells of 53 adult patients with AML M1 and M2 was determined. Also the relation between these expressions and the achievement remission in patients was searched. Two quantitative flow cytometry methods of the expression intensity analysis of CD58 and HLA-DR antigens were performed.
The analysis indicated that myeloblasts at diagnosis of patients with post chemotherapy remission (CR+) showed higher of both CD58 and HLA-DR intensity expression as compared to patients with no remission (CR-) despite intensive chemotherapy (p< 0.01).
Our results indicated that high expression intensity of studied molecules on leukemic myeloblasts might be beneficial factor for anti-leukemic activity of lymphocytes T and NK cells. Additionally, the level of expression CD58 and HLA-DR may be useful element in the AML remission prognosis.
keywords:

acute myeloid leukaemia, myeloblasts, CD58, HLA-DR, expression intensity

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe